Rathbones Group PLC Centessa Pharmaceuticals PLC Transaction History
Rathbones Group PLC
- $19.7 Billion
- Q4 2024
A detailed history of Rathbones Group PLC transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Rathbones Group PLC holds 16,650 shares of CNTA stock, worth $198,801. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,650
Previous 30,400
45.23%
Holding current value
$198,801
Previous $486,000
42.8%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CNTA
# of Institutions
117Shares Held
120MCall Options Held
7KPut Options Held
220K-
Medicxi Ventures Management (Jersey) LTD20MShares$238 Million75.25% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$119 Million99.89% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$116 Million5.81% of portfolio
-
Perceptive Advisors LLC New York, NY6.35MShares$75.8 Million3.55% of portfolio
-
First Light Asset Management, LLC Edina, MN5.81MShares$69.3 Million9.51% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.13B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...